Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies. J of Skin. 2021;5(6):s66. doi:10.25251/skin.5.supp.66